Portfolio

ABOUT: 
Napigen is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes and animals. The company is developing new gene editing technologies to provide potential cures for mitochondrial diseases.

Learn more at 
napigen.com


INVESTMENT: 
A $100,000 UMDF research grant
 has been converted to equity.

The MITO Fund logo

Interested in having
The Mito Fund
explore investment
in your company?

Click here to start a
conversation with us.

ABOUT:  
Pierrepont Therapeutics, Inc. is dedicated to developing targeted treatments for primary mitochondrial and other rare genetic diseases. Pierrepont’s lead product candidate, PTI-501 (formerly ENTR-501) is a proprietary intracellular enzyme replacement therapy for the treatment of MNGIE that is exclusively licensed from Entrada Therapeutics, Inc. (Nasdaq: TRDA). 

Learn more at www.PierrepontTx.com.

INVESTMENT: 
$500,000

MitoFund-Candle

Looking to support UMDF through Venture Philanthropy?